S-1/A: Apimeds Pharmaceuticals US, Inc. Eyes NYSE American Listing with $14.4 Million IPO

Apimeds Pharmaceuticals US, Inc. is seeking to list its common stock on the NYSE American through a $14.4 million initial public offering.

Summary

• Apimeds Pharmaceuticals US, Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its Form S-1 registration statement for a proposed initial public offering.
• The company is developing Apitox, a bee venom-based toxin, as a potential treatment for osteoarthritis (OA) and multiple sclerosis (MS).
• The IPO aims to raise approximately $14.4 million through the sale of 4,500,000 shares of common stock, with an anticipated offering price between $4.00 and $5.00 per share.
• Certain existing stockholders have indicated an interest in purchasing up to $6.0 million of shares in the offering.
• Inscobee Inc., a South Korean corporation, currently holds approximately 70.28% of Apimeds US's common stock and will hold 45.78% upon completion of the offering.
• The company intends to use the net proceeds from the offering to fund a Phase III clinical trial in knee OA, initiate non-registered company-sponsored trials in MS, cover manufacturing costs, and for general corporate purposes.
• Apimeds US believes there is a significant market opportunity in the United States for Apitox to enhance treatment of the lack of mobility and pain management symptoms associated with of OA and MS.
• According to Precedence Research, the OA therapeutics market size in the United States accounted for $8.28 billion in 2022 and it is expected to hit around $20.24 billion by 2032, expanding at a compounded annual growth rate, or CAGR, of 9.4% from 2023 to 2032.
• According to Pharmaceutical Technology the MS market size in the United States accounted for $10.73 billion in 2022 and is expected to hit $24.4 billion by 2030, expanding at a CAGR of 10.32%.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the potential of Apimeds' lead candidate and the risks associated with the company's financial position and the drug development process. The sentiment is neutral, reflecting the inherent uncertainties in the biopharmaceutical industry.

Positives

• Apitox has completed a positive Phase III trial in South Korea for the treatment of pain associated with Osteoarthritis in 2018.
• The company has a licensing agreement with Apimeds Korea for the rights to Apitox in the United States.
• The company intends to use a portion of the proceeds of this offering to facilitate the early prosecution of appropriate MS patient populations through non-registered corporate sponsorship studies.
• The company has an exclusive relationship with its supplier for pharmaceutical use in the United States and they are not permitted to sell to any other party for pharmaceutical use.

Negatives

• The company has incurred significant net losses since inception and anticipates that it will continue to incur substantial net losses for the foreseeable future and may never achieve profitability.
• The report of our independent registered public accounting firm included a going concern explanatory paragraph.
• The company has identified material weaknesses in its internal control over financial reporting, and the failure to remediate these material weakness may adversely affect our business, investor confidence in our company, our financial results and the market value of our common stock.
• The company is substantially dependent on our relationships with our principal stockholder, Apimeds Korea. The loss of this relationship would have a material adverse effect on our business.

Risks

• Clinical development has inherent risk in its process and our product candidate. Apitox, will be evaluated in a clinical environment for an indication which it has limited patient exposure which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
• Even after this offering, we may require substantial additional funding to finance our operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain parts of our development programs or other operations.
• We are dependent on the clinical success of Apitox in the treatment of symptoms of knee OA and MS in the United States.
• We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidate we develop, our commercial opportunities will be negatively impacted. Our product candidate will, if approved, also compete with existing branded, generic and off-label products.
• Our product candidate may cause undesirable side effects or have other properties that could halt its clinical development, prevent its regulatory approval, limit its commercial potential or result in significant negative consequences. In addition, even if approved, our products may cause significant adverse events, toxicities or other undesirable side effects identified during post-marketing surveillance, which could result in regulatory action or negatively affect our ability to market the product.
• We rely on principally on trade secrets and other forms of non-patent intellectual property protection, which are difficult to protect.

Future Outlook

Apimeds US aims to impact high unmet medical needs of symptoms and quality of life issues surrounding knee OA and MS. The company intends to initiate an additional Phase III trial in advanced knee OA and multiple company-sponsored trials in MS. They will also pursue potential collaboration arrangements and out-licensing opportunities and seek non-dilutive funding and grant awards to support clinical research and product candidate development.

Industry Context

The announcement highlights Apimeds' entry into the competitive biopharmaceutical industry, specifically targeting the OA and MS markets. The company's focus on Apitox, a bee venom-based therapy, positions it within the growing field of biologics and alternative pain management solutions. The document acknowledges the presence of numerous biotechnology and pharmaceutical companies in OA and MS, creating strong synergies for potential opportunities subsequent to demonstrated clinical success and FDA approval.

Comparison to Industry Standards

• The document mentions competitors including major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide.
• It also references academic institutions, government agencies, and other public and private research organizations.
• The document does not provide specific comparisons to industry standards or comparable companies, projects, and results.

Related Party Transactions

• The company has entered into a Business Agreement with Apimeds Korea, a principal stockholder, granting the company a sublicensable, royalty-bearing license to research, develop, manufacture and commercialize and sell Apitox in the United States.
• The company has entered into an intellectual property assignment agreement with Apimeds Korea and Dr. Christopher Kim, the company's Chairman and Chief Medical Officer and the founder of Apimeds Korea.
• The company has entered into a patent license agreement with Dr. Christopher Kim, the company's Chairman and Chief Medical Officer and the founder of Apimeds Korea.
• The company has received $660,000 in convertible notes from Apimeds Korea and Inscobee Inc.
• The company has received $250,000 in promissory notes from Inscobee Inc.

Stakeholder Impact

• Shareholders: Potential for increased value through successful drug development and commercialization, but also risk of dilution and financial losses.
• Employees: Opportunity for career growth and participation in the company's success, but also risk of job insecurity due to the company's financial situation.
• Patients: Potential access to new and innovative treatments for OA and MS, but also risk of side effects and limited availability.
• Suppliers: Opportunity for increased business through manufacturing and supply agreements, but also risk of contract termination due to the company's financial situation.
• Creditors: Risk of default on debt obligations due to the company's financial situation.

Next Steps

• Initiate an additional Phase III trial in advanced knee OA.
• Initiate multiple company-sponsored trials in MS.
• Pursue potential collaboration arrangements and out-licensing opportunities.
• Seek non-dilutive funding and grant awards to support clinical research and product candidate development.

Key Dates

Keywords

Apitox, Apimeds Pharmaceuticals, Initial Public Offering, Osteoarthritis, Multiple Sclerosis, Biopharmaceutical, Clinical Stage, Bee Venom, NYSE American, Inscobee